Despite the trial not meeting its primary endpoint, the high dose was well tolerated, with a safety profile comparable to the approved 600 mg dose and no new safety signals observed. These findings ...

Lexington Partners' Clark Peterson on how the secondary market remains undercapitalized, setting the stage for a robust buyer ...

Pura Advisory officially launches today, co-founded by three senior corporate finance professionals to provide hands-on, ...

U.S. stock futures point lower ahead of White House tariffs announcements expected to come after markets close today, and ...